Bailey David N, Briggs John R
Division of Laboratory Medicine, Department of Pathology, University of California, San Diego, CA 92103, USA.
Ther Drug Monit. 2004 Feb;26(1):40-3. doi: 10.1097/00007691-200402000-00009.
The binding of acetaminophen, lidocaine, phenobarbital, phenytoin, theophylline, and valproic acid to human serum alpha-1 acid glycoprotein (orosomucoid) and to human serum albumin separately in vitro was investigated using equilibrium dialysis of the unlabeled drugs. Each drug was studied at a therapeutic concentration. Alpha-1 acid glycoprotein was studied at one elevated and two physiological concentrations, whereas albumin was studied at one physiological and two low concentrations. The nonphysiological concentrations were consistent with those that might be seen in a variety of clinical conditions. Acetaminophen, phenobarbital, theophylline, and valproic acid showed negligible binding to alpha-1 acid glycoprotein. However, lidocaine and phenytoin demonstrated binding to this protein, and increases in the alpha-1 acid glycoprotein concentration produced decreases in the unbound (free) or "active" concentration of these two drugs. All drugs but acetaminophen bound to albumin, and decreases in the albumin concentration yielded increases in the unbound (free) or "active" concentration of the remaining 5 drugs. These findings are significant when lidocaine, phenytoin, phenobarbital, theophylline, or valproic acid are used in patients with clinical conditions that may affect the concentration of these two binding proteins.
使用未标记药物的平衡透析法,分别体外研究了对乙酰氨基酚、利多卡因、苯巴比妥、苯妥英、茶碱和丙戊酸与人血清α-1酸性糖蛋白(类粘蛋白)以及与人血清白蛋白的结合情况。每种药物均在治疗浓度下进行研究。α-1酸性糖蛋白在一个升高浓度和两个生理浓度下进行研究,而白蛋白则在一个生理浓度和两个低浓度下进行研究。非生理浓度与在各种临床情况下可能出现的浓度一致。对乙酰氨基酚、苯巴比妥、茶碱和丙戊酸与α-1酸性糖蛋白的结合可忽略不计。然而,利多卡因和苯妥英显示出与该蛋白的结合,且α-1酸性糖蛋白浓度的增加导致这两种药物的未结合(游离)或“活性”浓度降低。除对乙酰氨基酚外,所有药物均与白蛋白结合,白蛋白浓度的降低导致其余5种药物的未结合(游离)或“活性”浓度增加。当在可能影响这两种结合蛋白浓度的临床情况下使用利多卡因、苯妥英、苯巴比妥、茶碱或丙戊酸时,这些发现具有重要意义。